This 2013 randomized, double-blind, placebo-controlled phase 3 trial evaluated the efficacy and safety of naltrexone sustained-release (SR)/bupropion SR combination therapy in overweight and obese adults. A total of 1,496 participants with a BMI of 27–45 kg/m² and at least one comorbidity were randomized to receive either the combination therapy or
